ZINKENG ASONGANYI, Pharm.D., (firstname.lastname@example.org) is the system director for ambulatory pharmacy services at University of Texas Medical Branch in the greater Houston area. He has oversight for all facets of ambulatory practice including retail and specialty pharmacy services, oncology/non-oncology outpatient infusion, and integrating pharmacists into ambulatory clinics. Asonganyi is a 2012 graduate of the University of Findlay College of Pharmacy, Ohio and practiced for a few years before deciding to complete a health system pharmacy administration residency at Methodist Dallas Medical Center.
He is an active participant in ASHP, serving on the Section of Pharmacy Practice Leaders Advisory Group (SAG) on Management of the Pharmacy Enterprise and in local pharmacy organizations, including being a member of the Maryland Society of Health-System Pharmacists pharmacy leadership group. He recently served on the ASHP Specialty Pharmacy State of Practice in Hospitals and Health Systems – Future Directions Summit Steering Committee.
Health-system based specialty pharmacy is at a pivotal juncture and ASHP and SSPP are uniquely positioned to greatly impact some of the challenges we continue to face. The ASHP Health-System Specialty Summit was a great first step in this journey, to continue demonstrating the value of a clinically integrated model to drive superior clinical outcomes and reduction in total cost of care for our patients. Just like we collaborate with multidisciplinary teams to take care of our patients, health systems must band together and collaborate with external stakeholders like payers and manufacturers to prevent fragmentation of care and improve our access to LDD drugs and favorable payer contracts. Working together to establish a standard on how we provide optimal care and metrics will be a great way to tell a story on the value health-system specialty pharmacies bring. My personal philosophy is to continue to grow and learn as a practitioner and innovate pharmacy practice models. I am grateful to be nominated for this role, and I look forward to advocating for pharmacists and the role we play in managing this complex, high-risk therapies.